STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
A phase 1/2 trial of Toripalimab in sarcomas and uterine sarcoma, run by STORM Therapeutics LTD, now recruiting.
Overview
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas is a phase 1/2 interventional study registered as NCT06975293 by STORM Therapeutics LTD, with 107 participants planned, started 2025-05-05 and due to reach its primary completion in 2027-12-29. Interventions recorded: STC-15 in combination with toripalimab and STC-15 monotherapy.
Similar pages
not linked directly; found by shared links- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Toripalimab, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Shares Uterine sarcoma, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- TrialClinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.